Clinical Trials Browser

Phase 2 × Neuroendocrine Tumors × Ipilimumab × Clear all

NCT04079712 2026-03-18

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Phase 2 Active not recruiting

17 enrolled 12 charts

EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04969887 2026-02-27

MOST-CIRCUIT

Phase 2 Active not recruiting

Genital Neoplasms, Female, Neuroendocrine Tumors

NCT03420521 2024-01-09

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Phase 2 Terminated

9 enrolled 17 charts

Carcinoid Tumor, Neuroendocrine Tumors